KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

NEW YORK, Jan. 27, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna's initial public offering conducted on February 8, 2024 (the "IPO"), of the important February 7, 2025 lead plaintiff deadline.So what: If you purchased Kyverna common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.W ...